Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food and Age Effect on LY03017 Pharmacokinetics
NCT06793995Phase 1Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY03017 in Alzheimer's disease (AD), Parkinson's disease (PD) and schizophrenia (3 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum observed concentration up to 96 hours, Area under the concentration-time curve extrapolated to infinity up to 96 hours and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
LY03017
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)schizophrenia
Beyond the preview
Go deeper on NCT06793995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793995.